ACTIVE

EXO Biologics

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-2,3 M €-12,7 %over 1 year
Revenue0 €-100,0 %over 1 year
Equity2,9 M €-10,0 %over 1 year
Workforce5,6 ETP-62,7 %over 1 year

Identity

Source · BCE/KBO

EXO Biologics is a Public limited company incorporated in 2019. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège. It employs on average 5,6 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0732.982.379
Incorporation
29/08/2019
Legal form
Public limited company
Registered office
Boulevard de Patience et Beaujonc 3 box 2
4000 Liège · WallonieSee on map
Contributed capital
5 120 717,88 €
Latest accounts
31/12/2025
Average workforce
5,6 ETP
Joint committees (1)
  • 207
Signals
Good liquidityHealthy social debts

Financials

Source · NBB, 6 filings

Trend over 6 financial years

20252024202320222021
Income statement
Revenue0 €4,9 k €19,4 k €––
EBITDA-1,2 M €1,3 M €-3 M €-465,4 k €-2,2 M €
Operating result-1,9 M €-2,1 M €-6 M €-583,9 k €-2,3 M €
Net result-2,3 M €-2,1 M €-5,1 M €-392,6 k €-2,5 M €
Balance sheet
Equity2,9 M €3,3 M €4,8 M €-3,2 M €-3 M €
Total assets11,7 M €12,6 M €9 M €3,1 M €4,6 M €
Cash158,2 k €1 M €2,4 M €517,1 k €4,1 M €
Debts8,8 M €9,3 M €4,2 M €5,8 M €7,4 M €
Other
Workforce5,6 ETP15,0 ETP16,6 ETP––

Valuation

Indicative valuation

As an indication, this company is worth

between 2,5 M€ and 5 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

4 active · 4 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Jean Michel Foidart
Director29/08/2019 → 19/06/2029
Margarite Limited S. Etr.0846.675.089Represented by Dalton Colin
Director21/09/2022 → 19/06/2029
NOSHAQ PARTNERS0808.219.836Represented by Eric Brandt
Director11/09/2023 → 19/06/2029
Stijn Van Rompay
Managing director29/08/2019 → 19/06/2029

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Biotech Management & Consulting0741.644.479Represented by Hugues Wallemacq
Director11/09/2023 → 2024 accounts
Pieter Van Rompay
Director11/09/2023 → 2024 accounts

Other companies at this address

Boulevard de Patience et Beaujonc 3 4000 Liège
CompanyCBE no.
Abscint● Active
0749.828.410
Aeroforge● Active
1044.274.185
AMPACIMON● Active
0827.990.317
Amyl Therapeutics● Active
0758.775.372
BECARV● Bankrupt
0840.777.885
BE.SPINE● Active
1013.110.857
CATALYA● Active
0727.648.171
CEFALY Technology● Active
0870.578.661
DERMAX● Active
0667.730.677
DIANOSIC● Active
1034.558.646
DW Cefaly Holding● Active
0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active
1023.778.481
ExoXpert● Active
1003.807.666
EYED PHARMA● Active
0508.599.605
Hirundo Biosciences● Active
0681.855.065
HolyFox Invest● Active
1010.693.181
Hyloris● Active
0669.738.676
Hyloris Developments● Active
0542.737.368
Hyloris Pharmaceuticals● Active
0674.494.151
Hyloris Therapeutics● Active
1025.029.385

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelMicro modelMicro modelMicro model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202129/08/2019
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months17 months
Filing date16/07/202614/07/202516/07/202420/07/202306/10/202229/07/2021
General meeting16/06/202617/06/202518/06/202420/06/202320/09/202215/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 6 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202516/06/202616/07/2026FrenchPDF
Abridged model31/12/202417/06/202514/07/2025FrenchPDF
Abridged model31/12/202318/06/202416/07/2024FrenchPDF
Micro model31/12/202220/06/202320/07/2023FrenchPDF
Micro model31/12/202120/09/202206/10/2022FrenchPDF
Micro model31/12/202015/06/202129/07/2021FrenchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 2,5 M€ and 5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

4 active · 4 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Jean Michel Foidart
Director29/08/2019 → 19/06/2029
Margarite Limited S. Etr.0846.675.089Represented by Dalton Colin
Director21/09/2022 → 19/06/2029
NOSHAQ PARTNERS0808.219.836Represented by Eric Brandt
Director11/09/2023 → 19/06/2029
Stijn Van Rompay
Managing director29/08/2019 → 19/06/2029

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Biotech Management & Consulting0741.644.479Represented by Hugues Wallemacq
Director11/09/2023 → 2024 accounts
Pieter Van Rompay
Director11/09/2023 → 2024 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates04/11/2026
    Démission et nomination administrateur(s)
    PDF
  • Mandates30/09/2026
    Démission et nomination administrateur(s)
    PDF
  • Capital / shares23/01/2026
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - CAPITAL, ACTIONS
    PDF
  • Capital / shares20/12/2024
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - CAPITAL, ACTIONS
    PDF
  • Capital / shares13/09/2024
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - CAPITAL, ACTIONS
    PDF
  • Mandates21/06/2024
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates04/03/2024
    DEMISSIONS, NOMINATIONS
    PDF
  • Capital / shares16/02/2024
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - CAPITAL, ACTIONS
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts
Year
Identity
Incorporation
Name
Registered office
Annual accounts
Filings6 filings
Mandates
NOSHAQ PARTNERS
Margarite Limited S. Etr.
Stijn Van Rompay
Jean Michel Foidart
Biotech Management & Consulting
Pieter Van Rompay
Marcin Jurga
NOSHAQ
20192020202120222023202420252026202720282029
EXO Biologics
Boulevard de Patience et Beaujonc 3 bte 2, 4000 Liège
Director
Director
Managing director
Director
Director
Director
Director
Director
CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE
Registered addressPeriodSource
Boulevard de Patience et Beaujonc 3 bte 2, 4000 LiègeCurrent
accounts 2022 → 2025
Accounts 2025 · 2026-00323390
Boulevard Gustave Kleyer 17, 4000 Liège
accounts 2021
Accounts 2021 · 2022-20452448

Company names

Source · NBB annual accounts, CBE
NamePeriodSource
EXO BiologicsCurrent
accounts 2020 → 2025
Accounts 2025 · 2026-00323390

Events

  1. 2025
    Annual accounts 2025-2,3 M €↓
  2. 2024
    Annual accounts 2024-2,1 M €↑
  3. 2023
    Annual accounts 2023-5,1 M €↓
  4. 2022
    Annual accounts 2022-392,6 k €↑
  5. 2021
    Annual accounts 2021-2,5 M €↓
  6. 2020
    Annual accounts 2020-1,1 M €
  7. 29/08/2019
    IncorporationPublic limited company